Loading...
CytomX Therapeutics, Inc.
CTMX•NASDAQ
Healthcare
Biotechnology
$2.35
$0.16(7.31%)
CytomX Therapeutics, Inc. (CTMX) Financial Performance & Income Statement Overview
Review CytomX Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
36.45%
↑ 36.45%
Operating Income Growth
485.49%
↑ 485.49%
Net Income Growth
5700.88%
↑ 5700.88%
Operating Cash Flow Growth
-53.89%
↓ 53.89%
Operating Margin
24.37%
↑ 24.37%
Gross Margin
64.90%
↑ 64.90%
Net Profit Margin
28.19%
↑ 28.19%
ROE
-553.12%
↓ 553.12%
ROIC
74.46%
↑ 74.46%
CytomX Therapeutics, Inc. (CTMX) Income Statement & Financial Overview
Review CytomX Therapeutics, Inc.'s (CTMX) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $47.60M | $38.05M | $40.58M | $43.25M |
| Short Term Investments | $32.28M | $62.57M | $77.01M | $93.94M |
| Cash & Short Term Investments | $79.89M | $100.62M | $117.59M | $137.18M |
| Net Receivables | $1.96M | $3.10M | $3.35M | $2.77M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Current Assets | $4.79M | $3.58M | $3.24M | $3.12M |
| Total Current Assets | $86.63M | $107.31M | $124.18M | $143.08M |
| Property Plant & Equipment (Net) | $9.28M | $10.60M | $12.13M | $13.54M |
| Goodwill | $949000.00 | $949000.00 | $949000.00 | $949000.00 |
| Intangible Assets | $547000.00 | $583000.00 | $620000.00 | $656000.00 |
| Goodwill & Intangible Assets | $1.50M | $1.53M | $1.57M | $1.60M |
| Long Term Investments | $0.00 | $0.00 | $0.00 | $917000.00 |
| Tax Assets | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Non-Current Assets | $1.09M | $1.09M | $1.10M | $76000.00 |
| Total Non-Current Assets | $11.87M | $13.23M | $14.80M | $16.14M |
| Total Assets | $98.50M | $120.53M | $138.98M | $159.22M |
| Account Payables | $276000.00 | $1.09M | $1.42M | $611000.00 |
| Short Term Debt | $5.29M | $0.00 | $5.001M | $9.72M |
| Tax Payables | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred Revenue | $33.23M | $67.20M | $96.06M | $123.77M |
| Other Current Liabilities | $11.41M | $12.34M | $16.74M | $11.78M |
| Total Current Liabilities | $50.20M | $85.77M | $119.23M | $142.86M |
| Long Term Debt | $2.86M | $4.24M | $5.60M | $6.88M |
| Deferred Revenue Non-Current | $16.21M | $26.86M | $0.00 | $36.71M |
| Deferred Tax Liabilities Non-Current | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Non-Current Liabilities | $4.18M | $4.12M | $37.61M | $3.99M |
| Total Non-Current Liabilities | $23.25M | $35.22M | $43.20M | $47.59M |
| Capital Lease Obligations | $8.15M | $9.38M | $10.60M | $6.88M |
| Total Liabilities | $73.45M | $120.99M | $162.43M | $190.45M |
| Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock | $1000.00 | $1000.00 | $1000.00 | $1000.00 |
| Retained Earnings | -$668.05M | -$691.58M | -$710.46M | -$716.19M |
| Accumulated Other Comprehensive Income/Loss | -$1000.00 | $27000.00 | $40000.00 | -$4000.00 |
| Total Stockholders Equity | $25.05M | -$456000.00 | -$23.45M | -$31.23M |
| Total Equity | $25.05M | -$456000.00 | -$23.45M | -$31.23M |
| Total Liabilities & Stockholders Equity | $98.50M | $120.53M | $138.98M | $159.22M |
| Total Investments | $32.28M | $62.57M | $77.01M | $94.85M |
| Total Debt | $8.15M | $9.38M | $10.60M | $11.75M |
| Net Debt | -$39.45M | -$28.67M | -$29.98M | -$31.50M |
CytomX Therapeutics, Inc. (CTMX) Balance Sheet Analysis
CytomX Therapeutics, Inc. (CTMX) manages its money wisely, with plenty of -53.89% and 5700.88% to cover its bills. The company’s long-term debts are manageable, balanced by steady 28.19%. Shareholders’ stake in the business has grown thanks to smart decisions. Overall, the numbers show a solid position, giving it room to invest, expand, or adapt. For investors, this paints a promising picture for the future.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan